ABSTRACT
Since its launch, more than 9 million women worldwide have used the levonorgestrel IUS for contraception, as a treatment for heavy menstrual bleeding, and as the progestogen component of hormone replacement therapy (HRT). For women in their reproductive years, the IUS has become one of the most acceptable medical treatments for menorrhagia, reducing referrals to specialists and decreasing the need for operative gynecologic surgery.
